IPN Share Price

Open 104.00 Change Price %
High 105.75 1 Day 0.95 0.92
Low 103.95 1 Week 0.00 0.00
Close 104.75 1 Month -9.55 -8.36
Volume 65090 1 Year 43.44 70.85
52 Week High 129.85
52 Week Low 61.12
IPN Important Levels
Resistance 2 106.42
Resistance 1 105.73
Pivot 104.82
Support 1 103.77
Support 2 103.08
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLFCI 0.31 34.78%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
AVT 0.19 26.67%
ALFRE 1.81 25.69%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
CFI 2.01 20.36%
More..
EPA France Top Losers Stocks
MLROU 6.37 -34.19%
MLLEA 0.61 -23.75%
ALAUP 0.20 -13.04%
OXI 0.08 -11.11%
OXI 0.08 -11.11%
MLFXO 3.79 -9.98%
TONN 1.20 -9.77%
ALCLS 26.88 -9.22%
RUSAL 10.00 -9.09%
ALEUP 0.20 -9.09%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 2
As on 1st Nov 2017 IPN Share Price closed @ 104.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 99.11 & Strong Sell for SHORT-TERM with Stoploss of 113.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for November
1st Target up-side 113.66
2nd Target up-side 120.37
3rd Target up-side 127.07
1st Target down-side 94.54
2nd Target down-side 87.83
3rd Target down-side 81.13
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.